



ESTRO
36

5 - 9 May 2017
Vienna, Austria

FINAL ANNOUNCEMENT





DEADLINES

ESTRO and Company Awards: **18 October 2016**

Abstract submission: **24 October 2016**

Early registration: **18 January 2017**

Late registration: **4 April 2017**

Desk registration as of **5 April 2017**



TABLE OF CONTENTS

WELCOME LETTER	5
SCIENTIFIC AND ADVISORY COMMITTEES	6
PRE-MEETING COURSES	7
<i>Clinical pre-meeting course 7</i>	
<i>Interdisciplinary pre-meeting course 8</i>	
<i>Physics pre-meeting course 9</i>	
<i>GEC-ESTRO workshop 10</i>	
<i>RTT pre-meeting course 11</i>	
<i>Radiobiology pre-meeting course 12</i>	
CONTOURING WORKSHOPS	13
CALL FOR ABSTRACTS	14
SCIENTIFIC PROGRAMME	22
<i>Saturday 6 May 2017 22</i>	
<i>Sunday 7 May 2017 24</i>	
<i>Monday 8 May 2017 26</i>	
<i>Tuesday 9 May 2017 28</i>	
ESTRO FINANCIAL SUPPORT AND AWARDS	30
COMPANY FINANCIAL SUPPORT AND AWARDS	32
GENERAL INFORMATION	34
REGISTRATION	36
NOT TO BE MISSED...	38
<i>2017 ESTRO Communities Pavilion 38</i>	
<i>Super Run 38</i>	
ESTRO MEMBERSHIP	40



CONFERENCE SECRETARIAT

ESTRO Office
Rue Martin V, 40
1200 Brussels
Belgium

Tel.: +32 2 775 93 40
Fax: +32 2 779 54 94
events@estro.org

 WWW.FACEBOOK.COM/ESTRO.ORG

 [#ESTRO36](https://twitter.com/ESTRO36)

WWW.ESTRO.ORG

WELCOME LETTER

It is my privilege and great pleasure to invite you to ESTRO 36 that will take place 5-9 May 2017 in Vienna, Austria.

ESTRO is an interdisciplinary society where radiation oncologists, medical physicists, radiobiologists, brachytherapists and radiation therapists aspire to join forces with other organisations in the oncology field that share ESTRO's vision of excellence in cancer treatment. At ESTRO 36, we draw attention to the multidisciplinary and interdisciplinary components of our practice, with emphasis on the new opportunities that they represent for all professionals of oncology, not only in research but also in the daily care of patients.

The interdisciplinary component of the scientific programme will include sessions on the following topics:

- MR guided radiotherapy: the new standard of care in 10 years time
- Radiomics and imaging databases for precision radiation oncology
- From big data to better radiotherapy
- Costs and value of radiotherapy innovations: how to assess
- Challenges in proton radiotherapy
- Is there any ground for boost brachytherapy in the time of high precision IGRT/IMRT?
- Selection of patients and radiotherapy technique for APBI in the light of new phase III trial data
- Clinical evidence for hypofractionation in prostate cancer: what is the optimum?
- Oligometastatic disease
- Radiotherapy plus immunotherapy combination: rationale and results so far
- Immunotherapy
- Targeting tumour heterogeneity
- Response adapted treatment
- Patient Reported Outcomes (PROs) in radiotherapy
- Safety and clinical and cost effectiveness of multi-modality IGRT and ART
- Clinical impact of waiting times
- Strategies to increase safety in radiation oncology: how to make accidents less likely to occur

Meanwhile, the Scientific Programme Committee and Scientific Advisory Groups of ESTRO 36 work hard to develop an excellent multidisciplinary component for the scientific programme, a multidisciplinary which will also be highlighted in several joint sessions with other European and international oncology societies.

The educational aspects of ESTRO 36 will include pre-

meeting courses, contouring workshops, teaching lectures and multidisciplinary tumour board sessions.

As in previous conferences, ESTRO 36 will offer a Young Scientists track. This track is fully organised by our young members and it enables them to meet young colleagues, share common interests, network and start to build their own collaborative projects at an international level.

The ESTRO annual meetings can only become a successful scientific event due to the multitude of contributions coming via abstract submissions. The Scientific Programme Committee is committed to offering large visibility to promising abstracts by including them in the scientific symposia or via dedicated poster viewing sessions. We therefore, strongly encourage you to take note of the abstract submission deadline and to send your abstracts in due time.

Last but not least, all of the leading exhibitors will contribute to ESTRO 36, Europe's largest industrial exhibition in radiation oncology, offering the opportunity to view the latest radiotherapy technology and cancer treatment products.

Stay tuned for more information coming soon. We look forward to be welcoming you in Vienna.

With warm regards



Yolande Lievens
ESTRO 36 Chair



YOLANDE LIEVENS

SCIENTIFIC AND ORGANISING COMMITTEES

CHAIR OF THE CONGRESS

Y. Lievens (BE)

ESTRO 36 SCIENTIFIC PROGRAMME COMMITTEE (SPC)

Chair: Y. Lievens (BE)

Scientific Advisory Group (SAG) chairs:

R. Coppes (NL), SAG for Radiobiology
M. Krause (DE), SAG for Clinical Radiotherapy
C. Kirisits (AT), SAG for Brachytherapy
M. Mast (NL), SAG for Radiation Technology
G. Meijer (NL), SAG for Radiation Physics
K. Røe Redalen (NO), SAG of Young ESTRO Members
M. Spalek (PL) SAG of Young ESTRO Members

Members: M. Baumann (DE), A. Boejen (DK), S. Faithfull (UK), R. Garcia (FR), J. Lindegaard (DK), L. Mullaney (IE), L. Muren (DK), J. Overgaard (DK), P. Poortmans (NL), U. Ricardi (IT), K. Rouschop (NL), B. Wouters (CA), D. Zips (DE).

SCIENTIFIC ADVISORY GROUP (SAG) OF YOUNG ESTRO MEMBERS

Chairs: K. Røe Redalen (NO), M. Spalek (PL)

Members: J-E Bibault (FR), G. Borst (NL), L. Fog (DK), L. Mullaney (IE), K. Rouschop (NL), M. Schmid (AT), D. Thorwarth (DE), W. van Elmpt (NL).

SCIENTIFIC ADVISORY GROUP (SAG) FOR CLINICAL RADIOTHERAPY

Chair: M. Krause (DE)

Members: G. Borst (NL), C. Faivre-Finn (UK), E. Fokas (UK), K. Haustermans (BE), M. Høyer (DK), J. Kazmierska (PL), P. Lara (ES), E. Lartigau (FR), Y. Lievens (BE), L. Livi (IT), C. Marijnen (NL), U. Ricardi (IT), C. Rödel (DE), D. Zips (DE).

SCIENTIFIC ADVISORY GROUP (SAG) FOR BRACHYTHERAPY

Chair: C. Kirisits (AT)

Members: Å. Carlsson Tedgren (SE), C. Chargary (FR), J. Guinot (ES), J. Lindegaard (DK), R. Nout (NL), P. Papagiannis (GR), B. Pieters (NL), C. Polgar (HU), F-A Siebert (DE), V. Strnad (DE), L. Tan (UK).

SCIENTIFIC ADVISORY GROUP (SAG) FOR RADIATION PHYSICS

Chair: G. Meijer (NL)

Members: C. Clark (UK), A. Dekker (NL), C. Fiorino (IT), D. Georg (AT), B. Heijman (NL), N. Jornet (ES), B. McClean (IE), L. Muren (DK), T. Nyholm (SE), U. Oelfke (UK), P. Papagiannis (GR), M. Schwarz (IT), J-J Sonke (NL), D. Thorwarth (DE), U. van der Heide (NL) D. Verellen (BE).

SCIENTIFIC ADVISORY GROUP (SAG) FOR RADIOBIOLOGY

Chair: R. Coppes (NL)

Members: J. Alsner (DK), J. Bussink (NL), N. Cordes (DE), A. Kiltie (UK), M. Pruschy (CH), K. Rouschop (NL), R. Suwinski (PL), P. Van Luijk (NL), C. Vens (NL), M-C Vozenin (CH), B. Wouters (CA).

SCIENTIFIC ADVISORY GROUP (SAG) FOR RADIATION TECHNOLOGY

Chair: M. Mast (NL)

Members: B. Bak (PL) A. Boejen (DK), M. Coffey (IE), C. Dickie (CA), A. Duffton (UK), S. Johansen (NO), M. Kamphuis (NL), A. Kostovski (BiH), F. Moura (PT), D. Pasini (IT), P. Scherer (AT), A. Vaandering (BE).

PRE-MEETING COURSES

CLINICAL PRE-MEETING COURSE

Patient Reported Outcome Measures (PROMs) in radiotherapy research and clinical practice

FRIDAY 5 MAY 2017

Course directors: T. Holch (UK) and C. Grau (DK)

COURSE AIM

To provide an overview of the current and potential future roles of PROMs in radiotherapy research and routine care settings.

LEARNING OBJECTIVES

- To assess the role of PROMs in clinical practice and within clinical trials.
- To evaluate the use of PROM-based models to predict patient risk of toxicity after radiotherapy and ion beam therapy.
- To examine radiotherapy dose-volume relationships involved in normal tissue complication probability (NTCP).

WHO SHOULD ATTEND?

Clinicians, allied health care professionals and researchers interested in:

- Improving their knowledge of the current and future role of PROMs
- Improving patient outcomes in radiotherapy
- Developing models predicting risk of radiotherapy toxicity.

CONTENT

Session 1: The PROMs value in cancer care:

- Improved doctor-patient communication
- Improved outcomes.

Session 2: What are the methodological and practical challenges associated with the collection and use of PROMs?

- Selection of measures, time points; electronic vs paper
- Translation into different languages
- Patient understanding
- Non-compliance.

Session 3: Implementation in radiotherapy research and clinical practice in different cancers:

- REQUITE study (radiogenomics)
- Prostate lung cancer groups
- Head and neck
- Gynaecological.

Session 4: Correlating dose distribution and PROMs

Modelling NTCP relationship to CTCAE and why PROs might be better validated evidence of change from baseline

Session 5: Collection of electronic patient reported outcomes (ePROMs)

- Feasibility of completion during and after treatment
- Early evaluation indicators
- Patient and staff acceptance
- Longitudinal follow up.

Session 6: Standard of PROM reporting in trials

PRO Consort guidelines applied to clinical trial reporting

Session 7: Future directions and research priorities in the development of PROM measures and the applications of PROM data.

- Economics, relating PROMs to dose distribution
- Scalability of ePROM systems
- Cat vs traditional questionnaires.

Session 8: Discussion: How to integrate PROMs into clinical practice

Practical ideas towards implementation.

INTERDISCIPLINARY PRE-MEETING COURSE

Integration of multimodality imaging in radiation oncology to improve target definition and modified dose prescription

FRIDAY 5 MAY 2017

Course directors: U. van der Heide (NL) and D. Zips (DE)

LEARNING OBJECTIVES

- To learn how modern imaging technology such as functional MRI and PET influences today's radiotherapy.
- To better understand the concept how functional imaging can be used for better target definition and individual dose-prescriptions.
- To discuss with experts the current state-of-the-art in main disease sites including cancers of the prostate, lung, rectum, head and neck, brain and cervix.
- To understand limitations and potential pitfalls when using advanced imaging.
- To gain knowledge in how to implement advanced imaging in routine radiation oncology.

WHO SHOULD ATTEND?

Radiation oncologists, medical physicists, biologists and radiation therapists (RTTs) with interest in functional imaging for better radiation oncology. The course will provide "teaching level" lectures with basics for attendees who want to refresh their knowledge and in addition it will provide "in-depth" discussions with experts in specific indications.

CONTENT

Introduction, biology, imaging technology and transfer in radiation oncology

- Clinical background
- Imaging biology for radiation oncology
- Update advanced imaging technology including hybrid imaging
- Specific requirements and workflows to integrate multimodality imaging for target definition and modified dose-prescriptions
- Lessons learned: the example of DCE-MRI in radiation oncology

Disease-specific application of multimodality imaging in radiation oncology

- Prostate cancer
- Lung cancer
- Head and neck
- Rectal cancer
- Glioma
- Cervical cancer.



PHYSICS PRE-MEETING COURSE

Medical physics aspects of particle therapy

FRIDAY 5 MAY 2017

Course directors: M. Schwarz (IT) and J. Farr (USA)

COURSE AIM

The use of “heavy” charged particles (mostly protons and carbon ions) is an expanding modality in radiation oncology and such expansion is in advance of the number of trained medical physicists in the field. In addition, patients who may benefit from particle therapy are often referred from X-ray treatment facilities. To assist in external referrals, all therapeutic medical physicists should have some knowledge of particle therapy, and this course seeks to provide this introductory education. Due to the evolutionary nature of particle therapy, a balance of fundamental and current topics will be covered.

- Uncertainties and their dosimetric impact
- Treatment planning
- Motion management
- In-vivo dosimetry for patient dose verification
- Outlook and future directions of particle therapy.

LEARNING OBJECTIVES

Upon completion of the course, successful learners will be able to:

- Comprehend basic particle interactions with matter and radiobiology
- Compare aspects of particle therapy systems
- Know methods of particle beam dosimetry
- Discover insight into particle therapy specific imaging
- Know about acceptance testing and clinical commissioning
- Comprehend machine and patient specific quality assurance methods
- Critique particle therapy specific treatment planning techniques
- Compare particle therapy with photon therapy treatment plans
- Interpret particle therapy uncertainties, detections, and their mitigations
- Appraise how to select the most appropriate patient indications for particle therapy.

WHO SHOULD ATTEND?

The target group consists of medical physicists, medical physics assistants, dosimetrists and researchers who are interested in improving their knowledge of clinical particle therapy.

CONTENT

- Clinical perspective of particle beam therapy
- Particle beam interactions
- Radiobiology of particle beam
- Particle therapy systems
- Particle specific imaging
- Particle therapy detectors and sensors
- Acceptance testing of particle therapy systems
- Clinical commissioning of particle therapy systems

GEC-ESTRO WORKSHOP

Innovations in brachytherapy

FRIDAY 5 MAY 2017

Course directors: C. Kirisits (AT) and P. Petric (QA)

WORKSHOP AIM

Brachytherapy is a treatment modality with long tradition, based on standardised techniques and extensive experience of different schools for several decades. In the last years we have witnessed an increasing amount of exciting developments in terms of brachytherapy technology, imaging, intervention methods and dose delivery devices. In some cases, these developments have not yet reached the level of state of the art in general, but are discussed between different traditional “schools”. The aim of this workshop is to give an overview of some of the most promising new tools and techniques available. It will allow a moderated debate about pro’s and con’s and interactive discussion with the participants. The optimal use of each technique for each patient group will be discussed. Instead of comparing the technologies in a competitive manner, the workshop will aim to emphasise their complementarity.

LEARNING OBJECTIVES

- Discover the clinical benefits and limitations of different kinds of applicators for intracavitary and superficial brachytherapy techniques (including customised and 3D printed applicators)
- Distinguish dosimetric properties of shielded, rotational and electronic brachytherapy dose delivery devices
- Compare state of the art balloon and interstitial techniques for partial breast brachytherapy
- Interpret the evidence and experience with modern techniques for anorectal brachytherapy
- Justify the use of current state of the art prostate brachytherapy by comparison with modern external beam treatments
- Modify current practice by using MRI and different ultrasound approaches for prostate, gynaecological and anorectal interventions and treatment planning.

WHO SHOULD ATTEND?

- Radiation and clinical oncologists
- Physicists
- Radiologists
- Urologists
- Gynaecologists
- Surgeons
- Brachytherapy technologists
- Specialist nurses.

CONTENT

Session 1: Applicators

- New “standard” applicators
- Individualised 3D printed applicators
- Shielding techniques
- Electronic brachytherapy and superficial.

Session 2: Breast

- Balloon techniques
- Interstitial techniques.

Session 3: Anorectal

- Superficial
- Interstitial.

Session 4: Prostate

- Technological innovations for dose delivery
- Clinical innovations for targeted therapy
- Do we need brachytherapy when using modern external beam methods?

Session 5: Brachytherapy imaging

- Ultrasound versus MRI
- Transabdominal Ultrasound
- TRUS, TVUS, TRACE, TAUS & combinations.



RTT PRE-MEETING COURSE

Quality and risk management in practice

FRIDAY 5 MAY 2017

Course directors: M. Coffey (IE) and S. Johansen (NO)

COURSE AIM

The course aims are to give some practical approaches to risk management in the clinical setting and to explore some of the issues surrounding reporting.

LEARNING OBJECTIVES

On completion of this course, participants will be able to:

- Evaluate the issues surrounding reporting and how to address them in the clinical setting
- Consider how quality indicators, benchmarking and reporting and learning can be introduced into a department to improve overall quality of the service
- Participate in a lean exercise and evaluate its applicability in practice.

WHO SHOULD ATTEND?

The course is primarily for radiation therapists (RTTs) but is applicable to all professionals and trainees.

CONTENT

- A theoretical component on the background to risk management
- Legislation relating to risk management and how it is applied
- Benchmarking and how it is applied
- To report “or not” and the pressures influencing decisions.

RADIOBIOLOGY PRE-MEETING COURSE

Clinical application of biomarkers: How to discover, explore, and validate biomarkers for normal tissue toxicity and tumour response

FRIDAY 5 MAY 2017

Course directors: J. Alsner (DK) and M-C. Vozenin (CH)

COURSE AIM

Enable participants to understand the scientific and clinical aspects associated with discovery, exploration, and validation of biomarkers for personalised/precision radiation oncology (PRO) and raise awareness of key challenges in this important field.

Validation

- Design methodology for biomarker based radiotherapy trials
- Clinical trial example (EORTC-1219): Randomised prospective multicenter study testing a radiosensitizer and a predictive biomarker.

LEARNING OBJECTIVES

- To comprehend the basic principles of prognostic and predictive biomarkers
- To assess the relevance of biomarkers for normal tissue toxicity
- To assess the relevance of biomarkers for tumour response
- To propose strategies for validation of biomarkers
- To propose strategies for implementing imaging and molecular biomarkers for PRO
- To analyse legal and patent aspects for the clinical use of biomarkers.

WHO SHOULD ATTEND?

- Radiation oncologists, particularly those in the early stage of their career, who are keen to understand how biomarkers are important for PRO
- Radiation biologists seeking information on how to maximise the clinical impact of their scientific discoveries
- Radiation physicists and RTTs looking for an overview and update of recent and ongoing developments in the field of biomarkers.

CONTENT

Prognostic and predictive biomarkers

Tumour response

- Genetic biomarkers: mutations and mRNA / miRNA profiles
- Imaging biomarkers: PET / MR
- Imaging biomarkers: radiomics
- Circulating tumour cells and cell-free DNA / RNA.

Normal tissue

- Genetic biomarkers: genomic DNA
- Genetic biomarkers: mitochondrial DNA
- Proteomic / metabolomic biomarkers
- Functional biomarkers.

CONTOURING WORKSHOPS



FALCON (Fellowship in Anatomic DeLineation and CONtouring) is the multifunctional ESTRO platform for contouring and delineation. Eight such workshops have been planned for ESTRO 36.

PROGRAMME

- Intraprostatic relapses: Friday 5 May 2017 from 08:00-10:00 (repeated Saturday 6 May from 14:45-16:45)
- Liver SBRT: Friday 5 May 2017 from 10:30-12:30 (repeated Sunday 7 May from 14:45-16:45)
- Anal canal: Friday 5 May 2017 from 13:30-15:30 (repeated Monday 8 May from 14:45-16:45)
- Spine SBRT: Friday 5 May 2017 from 16:00-18:00 (repeated Tuesday 9 May from 08:30-10:30)

TARGET AUDIENCE

The delineation workshops are aimed at all radiation oncology professionals who want to improve their contouring skills.

STRUCTURE OF THE WORKSHOPS

- Presentation of the clinical case and the delineation exercise
- Explanation of the contouring software
- 20 minutes for the first delineation on site
- Presentation of the delineation guidelines
- 20 minutes for the second delineation on site
- Discussion between experts and participants.

PRACTICAL ARRANGEMENTS

- Participants should bring their own laptops
- Wifi and wired connection will be available
- Participants will be limited to 60 per workshop to keep a strong interactivity in the group.

ABOUT FALCON

FALCON workshops have been organised at ESTRO congresses since 2010 and have been growing steadily in popularity. Attending a FALCON workshop offers the opportunity for individual professionals to:

- Validate their contouring practice during live workshops by comparing them with those from experts and other participants
- Learn the indications proposed by the experts that coordinate the workshops
- Discuss with other participants, experts and panellists
- Communicate and use the delineation guidelines in order to further integrate them into daily practice.

COUNTOURING WORKSHOP FEES

	Initial Workshop	Additional Workshop
Student*/In Training Member**	€ 75	€ 25
Member	€ 100	€ 40
Non Member	€ 150	€ 50

*To register as a student you should be an ESTRO member and send a copy of your valid student card to events@estro.org before registering. Institute letters are not accepted.

**Members with specialty RTT may register at the In Training fee.

CALL FOR ABSTRACTS

GUIDELINES FOR SUBMISSION OF ABSTRACTS

ABSTRACT SUBMISSION DEADLINE: 24 OCTOBER 2016 (23.59 HRS)

GENERAL INSTRUCTIONS

Abstracts must be submitted on-line on the ESTRO website at: www.estro.org. For questions regarding the on-line submission process, please e-mail abstracts@estro.org.

REGULATIONS

With the submission of an abstract for ESTRO 36, the first (presenting) author:

- Accepts responsibility for the accuracy of the abstract and ascertains that all authors are aware of the content before submission
- Accepts to be the contact person for all correspondence related to the abstract and to inform the co-authors about its status
- Accepts to identify any financial interest in products or processes described in the abstract. This includes stock ownership, membership on any advisory boards, commercially sponsored research or any other substantial relationships.
- Certifies that the information to be reported is for exclusive presentation in the session to which the abstract will be assigned if accepted and that the information will not be presented as such at any commercially sponsored satellite symposia during the conference.

Abstracts must be submitted and presented at the conference in English. The Scientific Committee reserves the right to reject an abstract written in poor English.

Abstracts will be anonymised before review to ensure fairness and eliminate possible bias. Therefore it is **strictly forbidden** to include the authors' names or institutions in the body of the abstracts.

ABSTRACT FORMAT

- **Track:** choose a track keeping in mind that:
 - Abstracts submitted under the **Clinical track** are reviewed by clinicians and considered for the clinical track of ESTRO 36.
 - Abstracts submitted under the **Physics track** are reviewed by physicists and considered for the physics track of ESTRO 36.
 - Abstracts submitted under the **Radiobiology track** are reviewed by radiobiologists and considered for the radiobiology track of ESTRO 36.

- Abstracts submitted under the **Brachytherapy track** are reviewed by brachytherapists and considered for the GEC-ESTRO brachytherapy track of ESTRO 36.
- Abstracts submitted under the **RTT track** are reviewed by radiation therapists (RTTs) and considered for the RTT track only.

It is extremely important that you submit your abstract under the correct track. Submitting under the wrong track will result in your abstract being sent to the wrong experts for review and being scored low as a consequence.

• **Further advice for submitters:**

- **Delineation abstracts:** if the focus of the abstract is on imaging techniques, then the abstract should be submitted under the physics topics; if the focus of the abstract is on correctness of TV, OAR, then the abstract should be submitted under the clinical topics or under the RTT topics.
- **Brachytherapy abstracts:** abstracts on combination of BT and EBRT should be submitted under the clinical topics. Abstracts on BT and EBRT may also be submitted under the brachytherapy track topics if the focus of the scientific question is brachytherapy-related, however the submitter should be aware of the fact that, the track to which he/she submits may have an influence on the way the abstract is evaluated.
- **Clinical outcome:** If there is no clinical outcome (at least toxicity reporting) the abstract should be submitted under the physics topics (or brachytherapy topics).
- **Topic category:** choose the topic category that refers to the main subject of the abstract. The Scientific Committee reserves the right to re-categorise the abstract.
- **Keywords:** authors are required to select a keyword from a pre-defined menu. **The list of keywords corresponding to each topic category indicated in the table (next pages) can be a useful guide to determine the most appropriate topic category under which to submit the abstract.** When submitting your abstract only one keyword can be selected from the pre-defined list.
- **Presentation preference:** authors should indicate the presentation preference (oral, poster or no preference). Please note that the final decision on the presentation format rests with the Scientific Committee.



- **Title:** abstract titles should be brief and reflect the content of the abstract. The title (maximum 100 characters) is important since it focuses attention (it is the “showcase” for the presentation). Do not use capital letters in the title except for words that are always capitalised and do not use non-standard abbreviations.
- **Body of the abstract:** abstracts should be structured in such a way as to include (1) Purpose/Objective; (2) Material/methods; (3) Results; (4) Conclusion.
- **The use of standard abbreviations** is desirable. A special or unusual abbreviation must be placed (in round brackets) after the first appearance of the word for which it stands.
- **The on-line abstract submission procedure** will not accept abstracts that exceed 3,000 characters (body of the abstract, including spaces).
- Authors may include **one data table in the body of the abstract in JPG format** (this is not included in the number of characters) **AND one image (or TWO images) in JPG format**. The maximum file size of each image should be 500 KB. The maximum pixel size of the image is 600(w) x 800(h) pixel.
- **Equations** can be inserted in the text as images (only JPG format).
- **Oral presentation:** the abstract is selected for oral presentation at any of the proffered paper sessions.
- **Poster viewing:** posters selected for poster viewing sessions will be displayed in a central section of the poster area. Posters on a similar topic will be grouped together. The presenting authors of the selected posters in the group will visit all the posters within each group, along with the audience. At each poster, the presenting author will present his/her poster in 5 minutes, and then there will be 3 minutes for discussion, which will be led by two chairpersons for the group.
- **Poster presentation:** abstracts that have been selected for presentation in a poster format. The posters are grouped by topic and are displayed throughout the meeting. Only a limited number of abstracts will be selected for poster presentation.
- **E-poster:** abstracts are available for viewing in electronic format in special stations available at the conference venue.
- **Withdrawal of an abstract:** abstracts submitted for ESTRO 36 can be withdrawn **until 5 December 2016**. (To withdraw your abstract you should send an email to abstracts@estro.org). After this date, withdrawal of abstracts is no longer possible. Abstracts selected for oral / poster presentation should be presented at the meeting. If the first (presenting) author cannot attend the conference, he / she should assign a replacement and inform the ESTRO office of the replacement as soon as possible.

ABSTRACT SELECTION PROCESS

Abstracts submitted for presentation will be reviewed by an international panel of experts in the field of the subject. Abstract review criteria are based on clarity, supporting data, scientific rigour, potential significance, interest in the topic chosen and innovation or usefulness.

Abstracts on research obviously not yet performed and results not yet obtained will be banned.

Papers already accepted for publication will not be considered.

Abstracts will be selected for one of the following presentation formats:

Notification of outcome of abstract submission will be sent by email by end December 2016.

TOPICS

KEYWORDS (APPLIES TO ALL TOPICS)

CLINICAL	
Head and neck	Stereotactic radiotherapy
CNS	Intraoperative radiotherapy
Haematology	Brachytherapy
Breast	3D conformal
Lung	IMRT
Upper GI (oesophagus, stomach, pancreas, liver)	IGRT
Lower GI (colon, rectum, anus)	Functional imaging
Gynaecological (endometrium, cervix, vagina, vulva)	MRI guidance
Prostate	Delineation
Urology-non-prostate	Targeted therapy
Skin cancer/ malignant melanoma	Chemoradiotherapy
Sarcoma	Altered fractionation
Paediatric tumours	Dose escalation
Palliation	Particle therapy
Elderly	Normal tissue
Health services research / health economics	Aetiology
Communication	Personalised medicine
Other	Symptom control
	Shared decision making
	Quality of life
	Cost-effectiveness
	Cost/reimbursement
	Randomised controlled trial
	Guideline
	Patterns of care
	Other

TOPICS

KEYWORDS

PHYSICS	
Basic dosimetry and phantom and detector development	Dosimetry protocols
	Dosimetry fundamentals
	New detectors
	New phantoms
	Particle therapy
	Time resolved dosimetry
	Other
Dose measurement and dose calculation	Validation of dose calculation
	Characterisation of treatment equipment
	QA of treatment units/sources
	New dose calculation algorithms
	<i>In vivo</i> dose measurement
	Pre-treatment verification
	Other



Radiation protection, secondary tumour induction and low dose (incl. imaging)	Shielding calculations
	Dose monitoring
	Incidents and accidents
	Out-of-field dosimetry
	Modelling of secondary tumour induction
	Imaging dose
	Particle therapy
	Other
Treatment plan optimisation: algorithms	VMAT
	IMRT
	Protons
	Ions
	Beam angle optimisation
	Automated planning
	Robust planning
	Real-time planning
	Optimisation for dose painting
	Radiobiological optimisation
	Particle therapy
	Other
Treatment planning: applications	4D planning
	New treatment techniques
	Treatment technique comparison
	Radiobiological planning
	Particle therapy
	Other
(Radio)biological modelling	Outcome prediction
	Normal tissue complication probability models
	Tumour control models
	Data-mining and method for variable selection
	Multi-variable predictive models
	Modelling of hypo-fractionation particle therapy
	Other
Intra-fraction motion management	Immobilisation and positioning systems
	In room imaging/monitoring
	Motion prediction algorithms
	Gating
	Tracking
	Breathhold
	Particle therapy
	Other

Inter-fraction motion management (excl. adaptive radiotherapy)	Immobilisation and positioning systems
	In room imaging/monitoring (EPID, CBCT, US...)
	Correction protocols
	Margins
	Particle therapy
	Other
Adaptive radiotherapy for inter-fraction motion management	Clinical application
	Novel strategies
	Simulation of clinical impact
	Dose accumulation
	Particle therapy
	Other
CT Imaging for treatment preparation	4DCT
	Dual energy CT
	Synthetic CT
	Other
(Quantitative) functional and biological imaging	Pre-treatment imaging
	Use for dose painting
	Use for ART
	Response assessment and prediction
	Validation
	QA and technical aspects
	Other
Images and analyses	(Deformable) image registration
	Automatic contouring
	Contour propagation
	Geometrical accuracy
	Image quality
	Other
Implementation of new technology, techniques, clinical protocols or trials (incl. QA & audit)	Treatment units
	Treatment techniques
	Imaging equipment
	Risk and quality management
	Audits
	Other
Professional and educational issues	Application of EU directives
	Continuing professional education methodology
	Staffing levels
	Networks
	Other

TOPICS

KEYWORDS

BRACHYTHERAPY

TOPICS	KEYWORDS
Brachytherapy: breast	Indications
	Clinical outcome
	Image guidance
	Other
Brachytherapy: gynaecology	Cervix
	Endometrium
	Vulva
	Vagina
	Clinical outcome
	Image guidance
Brachytherapy: head and neck	Other
	Oral cavity
	Oropharynx
	Clinical outcome
Brachytherapy: physics	Image guidance
	Dose measurement
	Quality assurance
	Dosimetry
	Treatment verification
	Other
Brachytherapy: prostate	Image guidance
	Clinical outcome
	Indications
	Other
Brachytherapy: anorectal	Image guidance
	Clinical outcome
	Indications
	Contact brachytherapy
	Other
Brachytherapy: miscellaneous	Other
	Intraluminal brachytherapy
	Eye plaque brachytherapy
	Electronic brachytherapy
	Intraoperative brachytherapy
	Hepatobiliary
	Paediatric
	Sarcoma
Skin	

TOPICS

KEYWORDS

RADIOBIOLOGY	
Normal tissue biology of the heart	Stem cells Signalling Radiation protectors Other
Normal tissue biology of the lung	
Normal tissue biology of central nervous system	
Radiobiology of the intestinal track	
Radiobiology of skin	
Normal tissue radiobiology others	
Radiobiology of proton and heavy ions	Protons
	Carbon and heavy ions
	RBE effect
	Volume effects
Radiobiology of head and neck cancer	DNA repair
Radiobiology of prostate cancer	
Radiobiology of breast cancer	
Radiobiology of lung cancer	
Radiobiology of colorectal cancer	
Radiobiology of cancer others	Biomarkers and biological imaging Tumour biology and microenvironment Molecular targeting agents Cellular radiation response

TOPICS

KEYWORDS(APPLIES TO ALL TOPICS)

RTT

Patient preparation, positioning and immobilisation	Support aids 4DCT PET-CT MRI
Imaging acquisition and registration, OAR and target definition	Rigid and non-rigid registration Delineation of OAR Target definition Margins calculation
Treatment planning and dose calculation / QC and QA	Motion control IMRT 3DCRT Rotational therapy
Image guided radiotherapy and verification protocols	Brachytherapy MRI-Linac Proton therapy Gamma Knife
Motion management and adaptive strategies	Robotic radiotherapy Stereotactic radiotherapy Hypofractionation Quality control
Patient care, side effects and communication	Quality assurance Plan comparison IGRT ART
Education and training / role development	IGART Verification protocols Safety margins Side effects
Risk management / Quality management	Psycho-social support Palliative radiotherapy Incident reporting Clinical workflow Communication Quality management Review clinics Follow up Patient education Education of radiation therapists

SCIENTIFIC PROGRAMME

SATURDAY 6 MAY 2017

08:00 - 08:40	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE
	The role of radiotherapy in small cell lung cancer-current status and future developments	Immunotherapy	MRI for RO physicists: what is what? QA geometrical distortions	Cavity Theory: how can we separate the facts from the myths?
08:45 - 10:00	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM
	How to move forward in NSCLC?	Radiotherapy plus immunotherapy combination: rationale and results so far The immune-modulatory effect of radiotherapy on the tumour micro-environment: friend or foe? - The impact of tumour infiltrating lymphocytes on clinical outcome after (chemo)radiotherapy - Radiotherapy and immunotherapy combination: paradigm changing or just hype?	Particle therapy I	CT imaging, new developments Current status and potential of dual energy and spectral CT - New CT reconstruction methods for artifact reduction and optimised image quality - The potential of new CT technologies for radiotherapy with photons and protons
10:00 - 10:30	COFFEE BREAK			
10:30 - 11:30	MULTIDISCIPLINARY TUMOUR BOARD	SYMPOSIUM	PROFFERED PAPERS	PROFFERED PAPERS
	HNSCC	Response adapted treatment Mechanisms and biomarkers of tumour response heterogeneity - Response optimised treatment planning and guidance - Current status and future perspective of response adaptation		
11:40 - 12:10	VAN DER SCHUEREN AWARD LECTURE			
12:10 - 12:40	IRIDIUM AWARD LECTURE			
12:40 - 13:00	HONORARY PHYSICIST AWARD LECTURE			
13:00 - 14:45	LUNCH, SATELLITE SYMPOSIUM, POSTER VIEWING		13:30 - 14:30 PHYSICS MEMBERS ASSEMBLY	
14:45 - 16:00	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM
	The optimal approach to treat oligometastatic disease: different ways to handle an indication quickly gaining acceptance Clinical approach to abscopal effects - What is the purpose of surgical metastasectomy and do we achieve it? - What is the indication and what is the aim of clinical treatment: radiotherapy - What is the indication and what is the aim of clinical treatment: systemic treatment	Targeting tumour heterogeneity Using heterogeneous brachytherapy dose distribution to target tumour cell heterogeneity - The challenges of targeting tumour heterogeneity in the field of radiation oncology - The impact of tumour heterogeneity on radiation therapy outcomes	Particle therapy II	Imaging for therapeutic response / toxicity evaluation Functional imaging as biomarker for toxicity response - Imaging tumour response to neoadjuvant treatment in GI tumours - Imaging in animals
16:00 - 16:30	COFFEE BREAK			
16:30 - 17:30	PROFFERED PAPERS	SYMPOSIUM	PROFFERED PAPERS	PROFFERED PAPERS
		Oligometastatic disease		
17:40 - 18:25	HONORARY MEMBERS AWARD LECTURES			
18:30 - 19:30	POSTER AWARDS CEREMONY			

TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE			
High tech or low tech for metastatic disease, how does one decide and what is the cost-benefit?	Gene editing: how this technique can be used to study radiation responses?	Target delineation and target definition for PBI			
SYMPOSIUM	SYMPOSIUM	SYMPOSIUM		POSTER VIEWING	
High tech or low tech for metastatic disease, how does one decide and what is the cost-benefit? Palliative workflow - Evaluation of time, attendance of medical staff, and resources during stereotactic radiotherapy / radiosurgery: QUIRO-DEGRO trial - High tech approaches for curative treatment, when is enough enough?	Novel approaches in heart matters State of the art in heart effects - Pharmacological modulation of cardiac radiation injury	Expanding brachytherapy indications How the interventional radiologist can support brachytherapy implantations - The technique for CT/MR guided hepatic implantations - Tracking technologies for navigation in brachytherapy implantations - Using multiparametric US to redefine target volumes in brachytherapy			
PROFFERED PAPERS	SYMPOSIUM	PROFFERED PAPERS	PROFFERED PAPERS	POSTER VIEWING	
	Novel approaches in gut matters State of the art in gut effects - Novel developments in mechanisms and prevention of gastrointestinal toxicities				
SYMPOSIUM	SYMPOSIUM	SYMPOSIUM		POSTER VIEWING	CONTOURING WORKSHOP
Immobilisation and motion management, including comfort for patients Immobilising the patient to be as comfortable as possible. A general overview - Motion control of the patient, using the exactrac system - Motion of liver tumours using Active Breathing Control: keeping the margins small and the patient comfortable	Novel approaches in brain matters Effect of radiation on CNS stem cells - Amelioration of CNS damage using stem cell approaches	Brachytherapy pays Introducing the GEC-HERO initiative - Current knowledge on QALY for brachytherapy - Optimal utilisation of brachytherapy in Europe - can it be measured? - Economic evaluation of radiotherapy including brachytherapy for cancer – pitfalls			
PROFFERED PAPERS	SYMPOSIUM	PROFFERED PAPERS	PROFFERED PAPERS	POSTER VIEWING	
	Novel approaches in particle biology The ESTRO initiative on biological effects of particle therapy - RBE of protons - A small animal tumour model for low-energy laser-accelerated particles - Novel models in particle biology research				



08:00 - 08:40	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE
	Role of radiotherapy in extranodal lymphomas	Strategies to increase safety in radiation oncology: how to make accidents less likely to occur	Automated planning, knowledge-based planning and other novel developments in treatment planning - how do they work and perform?	Building of NTCP models that contain non-dosimetric parameters
08:45 - 10:00	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM
	New developments in Personalised Radiation Oncology (PRO) E-health and PRO: mobile technology and wearable sensors - Integration and analysis of complex data for PRO - Innovative clinical trial designs for PRO - Decision support systems and shared decision making	Safety and clinical and cost effectiveness of multi-modality IGRT and ART What evidence is needed to assess cost-effectiveness of new technology and how can we get it (easily)? - Tips and tricks for safe and effective routine clinical application - Do we have the (software) tools for safe application? - Development of procedures for safe clinical application of plan-of-the-day adaptive radiotherapy	Robust optimisation in protons and photons What is the actual robustness of the plans we deliver in clinical particle therapy practice, and what measures do we take to obtain it? - Minimax robust optimisation applied to IMPT for oropharyngeal tumours - Clinical implementation of coverage probability planning in cervix cancer	Ultra fast online therapy adaptation (replanning, dose accumulation QA) Automatic image segmentation for on-line adaptive RT - Ultrafast treatment planning and dose reconstruction - Online tumour tracking - technology and quality assurance
10:00 - 10:30	COFFEE BREAK			
10:30 - 11:30	MULTIDISCIPLINARY TUMOUR BOARD	SYMPOSIUM	PROFFERED PAPERS	PROFFERED PAPERS
	Lymphoma	Clinical impact of waiting times		
11:40 - 12:10	PRESIDENTIAL SYMPOSIUM			
12:10 - 12:30	JENS OVERGAARD LEGACY AWARD			
12:30 - 13:00	REGAUD AWARD LECTURE			
13:00 - 14:45	LUNCH, SATELLITE SYMPOSIUM, POSTER VIEWING			
14:45 - 16:00	SYMPOSIUM	SYMPOSIUM	DEBATE	PROFFERED PAPERS
	New paradigm in HNSCC Modern biomarkers for therapeutic strategy: radiation dose or volume modification - The changing role of the head and neck surgeon in HPV-positive oropharyngeal squamous cell carcinoma, or do we still need surgery? - Radiation de-escalation strategies in HPVpositive squamous cell carcinoma	Costs and value of radiotherapy innovations: how to assess Health Technology Assessment: what's in a word? - Radiotherapy costs: the good, the bad and the ugly - Method of development of ESMO Magnitude of Clinical Benefit applicable for radiotherapy	This house believes that proton guided photons will be superior to photon guided protons	
16:00 - 16:30	COFFEE BREAK			
16:30 - 17:30	PROFFERED PAPERS	SYMPOSIUM	PROFFERED PAPERS	PROFFERED PAPERS
		Global Task Force on Radiotherapy for Cancer Control		
17:40 - 17:50	ACADEMIC AWARD LECTURE: JACK FOWLER UNIVERSITY OF WISCONSIN AWARD			
17:50 - 18:10	COMPANY AWARD LECTURES: ESTRO-VARIAN AWARD AND ESTRO-ACCURAY AWARD			

TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE			
Particle therapy: how to start up and carry out daily clinical practice	Three-dimensional organoid culture system	Commissioning of dose calculations in brachytherapy TPS			
SYMPOSIUM	SYMPOSIUM	SYMPOSIUM		POSTER VIEWING	
Particle therapy: how to start up and carry out daily clinical practice RTTs skills for proton therapy – how and what to include in a learning programme - How to start up a proton therapy department – the point of view of a RTT - Workflow in a proton therapy department – real difference from photon therapy?	Combining tumour and normal tissue models Novel approaches in the study of bladder cancer - Combining tumour and lung tissue radiation	Paediatric brachytherapy The AMORE concept and late effects outcome for paediatric brachytherapy - Brachytherapy for bladder/prostate rhabdomyosarcoma: clinical outcome and functional results - Intraoperative HDR in paediatric brachytherapy			
PROFFERED PAPERS	PROFFERED PAPERS	PROFFERED PAPERS	PROFFERED PAPERS	POSTER VIEWING	
13:30 - 14:30 GEC-ESTRO ASSEMBLY					
SYMPOSIUM	PROFFERED PAPERS	SYMPOSIUM		POSTER VIEWING	CONTOURING WORKSHOP
Focus on ART: the clinical difficulties Multi-parametric functional PET/MR imaging for RT individualisation - Metabolic and functional MRI for glioblastoma dose-painting trial - RAIDER study on plan of the day and dose-escalation for bladder cancer		Registration and fusion techniques Rigid registration techniques for different imaging modalities - Deformable registration for dose summation - Imaging and fusion techniques for focal brachytherapy			
PROFFERED PAPERS	PROFFERED PAPERS	PROFFERED PAPERS	PROFFERED PAPERS	POSTER VIEWING	



08:00 - 08:40	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE
	State of the art multimodality treatment of rectal cancer	SBRT for vertebral metastases: experimental or routine practice?	Challenges in proton radiotherapy How to reduce range uncertainties Adaptation to anatomical changes: needs and pitfalls	HDAC inhibitors and chromatin
08:45 - 10:00	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM
	Rectal cancer – prediction and individualisation Sequence of radiotherapy, chemotherapy, and surgery: current concepts and trials Organ preservation by optimised chemoradiotherapy: ready for prime time? Imaging and molecular profiles to predict response to chemoradiotherapy: where do we stand?	Radiotherapy of brain tumours Radiotherapy for low grade glioma in adults: risk group stratification and clinical evidence What is the role of combined chemoradiotherapy for grade III glioma in adults? “Paediatric” brain tumours in adults	MR guided radiotherapy: the new standard of care in 10 years time Clinical opportunities with MR guided external beam radiotherapy MR guided brachytherapy - successes and potential future developments Challenges associated with MR guided radiotherapy Can we perform RCTs evaluating MR guided radiotherapy?	Novel approaches in head and neck tumour control State of the art in head and neck tumour radiobiology Novel developments in the radiobiology of HPV-positive head and neck tumours
10:00 - 10:30	COFFEE BREAK			
10:30 - 11:30	PROFFERED PAPERS	MULTIDISCIPLINARY TUMOUR BOARD	SYMPOSIUM	SYMPOSIUM
		Brain metastases	Radiomics and imaging databases for precision radiation oncology	Novel approaches in prostate tumour control State of the art in prostate tumour radiobiology Novel developments in molecular targeting of prostate cancer
11:40 - 11:50	DONAL HOLLYWOOD AWARD			
11:50 - 12:30	HIGHEST SCORING ABSTRACTS			
12:30 - 13:00	BREUR AWARD LECTURE			
13:00 - 14:45	LUNCH, SATELLITE SYMPOSIUM, POSTER VIEWING			
14:45 - 16:15	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM
	Non-rectal GI tumours: key open questions to be answered from (and for) the radiation oncologist! Radio(chemo)therapy in oesophageal cancer: can we do better? Does radiotherapy still have a role in the management of pancreatic cancer? Standard treatment in anal cancer: where do we stand and where should we go?	Locally advanced breast cancer Personalised local and locoregional radiotherapy in breast cancer Where should we place radiotherapy in high risk cases: before or after surgery? Radiotherapy after complete response after neoadjuvant CHT. Is it needed?	From big data to better radiotherapy	Novel approaches in lung tumour control State of the art in lung cancer radiobiology Secretome as novel target for lung cancer
16:15 - 16:45	COFFEE BREAK			
16:45 - 17:45	PROFFERED PAPERS	PROFFERED PAPERS	SYMPOSIUM	SYMPOSIUM
			Patient Reported Outcomes (PROs) in radiotherapy Differences between PRO and clinician reported morbidity and associations to clinical outcome Collecting PROs in routine clinical practice to assess radiotherapy toxicity and develop normal tissue complication probability models PROs instruments used in clinical trials	Novel approaches in colorectal tumour control State of the art in colorectal cancer Immunobiology of gastro-intestinal tumours
17:50	ESTRO GENERAL ASSEMBLY			

TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE		
State of the art and future improvements in in-room cone beam CT image quality	Radiomics for physicists – understanding feature extraction, quality, selection, prediction modelling, statistics, performance validation and possible applications of radiomics in clinical routine	Focus on lung cancer: what a radiotherapy department should offer their patients	“Show me the money”: tips and tricks on how to write successful grant proposals		
SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	CAREER SYMPOSIUM	POSTER VIEWING	
Experimental therapies - Grid therapy - Strategies for radiosensitisation with gold nanoparticles - Potentials of Cerenkov imaging in radiotherapy	Adaptive radiotherapy (both anatomical and “functional” changes) - Image registration and dose accumulation - Adaptive strategies to account for anatomical changes - Adaptive strategies to account for functional changes	Focus on lung cancer: what a radiotherapy department should offer their patients - Optimal delineation - ART in lung cancer: when and for whom? - Improvements in physics, DIBH in lung	Education and research grants - ERC grants - how to succeed - ESTRO educational grants and mobility grants		
PROFFERED PAPERS	PROFFERED PAPERS	PROFFERED PAPERS	KEYNOTE LECTURE	POSTER VIEWING	
DEBATE	PROFFERED PAPERS	SYMPOSIUM	SCIENTIFIC SYMPOSIUM	POSTER VIEWING	CONTOURING WORKSHOP
		Focus on prostate cancer: what is the best radiotherapy we need to treat our patients with - What are the best ingredients to deliver the optimal radiotherapy for prostate cancer? - Spacer / hypofractionation - Using an MR Linac for prostate cancer patients	Young ESTRO meets ESTRO School - Introduction and presentation of FALCON (Fellowship in Anatomic delineation and CONtouring) on-line contouring system as a tool for e-learning - Lung cancer - Cervical cancer - Rectal cancer		
PROFFERED PAPERS	PROFFERED PAPERS	PROFFERED PAPERS		POSTER VIEWING	
			16:45-17:00 - Info from Young ESTRO Activities and short report from Agora - 17:00-17:15 - Interactive quiz - 17:15-18:00 - Young networking		



08:30 - 09:10	TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE
	New radiotherapeutic horizons in soft tissue sarcoma treatment	Clinical evidence for hypofractionation in prostate cancer: what is the optimum?	Microvesicles and circulating tumour/DNA in radiation oncology
09:15 - 10:30	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM
	Radiotherapy in the elderly Radiotherapy in elderly rectal cancer patients - Breast cancer - Glioblastoma - Lung	Selection of patients and radiotherapy technique for APBI in the light of new phase III trial data Target coverage and dose to organs at risk using different techniques of APBI (EBI, IORT, BT) - External beam partial breast irradiation: changing patient selection based on current evidence - Partial breast irradiation with brachytherapy: changing patient selection based on current evidence	Novel approaches in poor tumour control sites Use of radiopharmaceuticals in pancreatic cancer - Contribution of microenvironment of malignant gliomas to angiogenesis - mRNA-based vaccines and Lewis lung cancer
10:30 - 11:00	COFFEE BREAK		
11:00 - 12:00	SYMPOSIUM	SYMPOSIUM	SYMPOSIUM
	Hypofractionation in prostate cancer Moderate hypofractionation in prostate cancer: what have we learnt from phase III trials - Extreme hypofractionation – the future of prostate care or repeating past mistakes? - Hypofractionation in prostate cancer: a word of caution	Is there any ground for boost brachytherapy in the time of high precision IGRT/IMRT? The efficacy of IGRT/IMRT simultaneous integrated boost (SIB) in gynaecology and breast - Dose gradients: the effect of high doses inside the CTV comparing boost brachytherapy with SIB - Why use invasive techniques for boost if IGRT is more comfortable for the patient?	Novel approaches in tumour control Molecular mechanisms of radiation-induced in situ tumour vaccination - Novel developments in paediatric cancer
12:00 - 13:00	CLOSING DEBATE		
13:00	CONCLUSIVE REMARKS		

TEACHING LECTURE	TEACHING LECTURE	TEACHING LECTURE	CONTOURING WORKSHOP
Update in nuclear medicine for radiation oncology	Basics, implementations, limitations... of Monte Carlo dose calculation algorithms	New roles in advanced practice for RTTs	
SYMPOSIUM	SYMPOSIUM	SYMPOSIUM	
4D imaging and tracked delivery MLC tracking: from bench to bedside - Motions models and tracking using MR - Tracking using electromagnetic transponder	Modelling and treatment customisation Developments in head and neck toxicity data, models, and treatment optimisation - New NTCP data in the thoracic region - New NTCP data in the pelvic area	Radiotherapy is technology driven. How to keep the patient involved?	
SYMPOSIUM	SYMPOSIUM	DEBATE	
Applications and challenges in dosimetry for MR-linacs Pre-treatment phantom dosimetry: effects in different phantoms and detectors - Reference dosimetry: getting the basics and calibration right - Clinical commissioning of MR guided treatment systems	Novel approaches for combining imaging and non-imaging data for radiotherapy response prediction Modelling the relation among volume, vascularisation and radio-sensitivity in cervical cancer exploiting Doppler ultrasonography data - Machine learning and bioinformatics approaches to combine MP data for outcome prediction - Tissue classification models based on imaging and non-imaging data	Lost in technology. More and more technology involved in patient treatment - are we still interacting with patients?	

ESTRO FINANCIAL SUPPORT AND AWARDS



AMBASSADOR SOLIDARITY FUND

The Ambassador Solidarity Fund is generously financed by part of the membership fee paid by the Supporting Ambassador members and enables sponsorship of individual In Training membership and registrations to ESTRO 36 to help young radiation oncology professionals from European economically challenged countries. More information on our webpage: <http://www.estro.org/members/individual-membership/supporting-ambassador>

20 sponsored registrations and In Training memberships are available for ESTRO 36.

CRITERIA FOR ELIGIBILITY

Applicants should be:

- Below 40 years old
- Currently be in training
- From economically challenged European countries (eligible countries: Albania, Bosnia & Herzegovina, Belarus, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Italy, Latvia, Lithuania, Moldova, Poland, Portugal, Romania, Russian Federation, Serbia, Slovak Republic, Slovenia, Spain, Turkey)
Applicable only to those who are unable to meet the cost of membership and registration without financial support.
- Active in the field of radiotherapy, radiobiology, radiation physics, or radiation technology
- Previous recipients of a grant are not eligible to apply.

HOW TO APPLY

Candidates should submit a curriculum vitae and a recommendation letter from their department head stating they are currently in training and that financial support is essential to register for membership and benefit from a sponsored registration to ESTRO 36.

Deadline for submission: 30 October 2016

Applications for the solidarity fund are to be addressed to:

Myriam Lybeer
mlybeer@estro.org

ESTRO MEMBERS FROM EMERGING COUNTRIES

ESTRO members from emerging countries can benefit from reduced registration fees to attend the conference. The list of eligible countries applies to individuals from low-income and lower-middle-income economies according to the World Bank listing available at: <http://data.worldbank.org/about/country-and-lending-groups>.

POSTER AWARDS

ESTRO sponsors four poster awards of € 1,000 each for a clinician, a physicist, radiation therapist (RTT) and a radiobiologist (respectively).

CRITERIA FOR SELECTION

- Only abstracts accepted for poster presentation for ESTRO 36 will be considered for the award.
- Posters are evaluated on (in decreasing order of importance): the scientific value of the data, the clarity of the presentation, and the visual quality of the poster layout.

HOW TO APPLY

No application is needed. You are automatically considered if your abstract is accepted.

Prizes will be handed out at the ESTRO 36 poster reception on Saturday 6 May 2017.



YOUNG SCIENTISTS POSTER AWARDS

ESTRO sponsors four young scientists poster awards consisting of a complimentary registration to a future ESTRO course for a clinician, physicist, radiation therapist (RTT) and radiobiologist (respectively).

CRITERIA FOR SELECTION

- Only abstracts accepted for poster presentation for ESTRO 36, by authors under 40 years of age, will be considered for the award.
- Posters are evaluated on (in decreasing order of importance): the scientific value of the data; the clarity of the presentation; and the visual quality of the poster layout.

HOW TO APPLY

No application is needed. You are automatically considered if your abstract is accepted.

Prizes will be handed out at the Young Scientists Reception on Monday 8 May 2017.



ESTRO - JACK FOWLER UNIVERSITY OF WISCONSIN AWARD 2017

A prize of € 1,000 will be given for the best abstract in the field of radiation physics or radiation technology, submitted for ESTRO 36.

CRITERIA FOR ELIGIBILITY

- Candidates should be ESTRO members.
- Candidates should be younger than 36. Exceptions will be made for female applicants who had to interrupt their research for pregnancy/maternity reasons; for them the maximum age is fixed at 40.

HOW TO APPLY

Candidates should submit:

- A curriculum vitae
- A letter from their department head stating that the work has been done by the applicant
- A copy of the abstract on radiation physics or radiation technology which should have been submitted for ESTRO 36 (indicate abstract title and submitting author with your application)

Deadline to apply: 18 October 2016

COMPANY FINANCIAL SUPPORT AND AWARDS



ESTRO - ACCURAY AWARD

A prize of € 7,500 will be given to a radiotherapy professional for research in the field of “High Precision Radiotherapy”. Awardees should be qualified in the field of clinical radiotherapy, radiation physics, radiation technology or radiobiology.

CRITERIA FOR ELIGIBILITY

- Candidates should be ESTRO members, having completed the submitted work in the previous or current year
- Submissions should be brought forward by the candidates and may be work done as an individual piece of research or as a thesis completed in the field of biological, physical or clinical research
- Candidates should be younger than 36. Exceptions will be made for female applicants who had to interrupt their research for pregnancy/maternity reasons; for them the maximum age is fixed at 40.

HOW TO APPLY

Candidates should submit:

- A curriculum vitae and a list of publications
- A copy of the abstract on the project which should have been submitted for ESTRO 36 (indicate abstract title and submitting author with your application)
- A summary (in English) of their work (max 2 pages).

Candidates should also commit themselves to write an original paper in English on (part of) the scientific work carried out. This paper should be based on previously unpublished data and should be written according to the “Instructions to authors” of the Journal *Radiotherapy & Oncology* in which it will be published if accepted.

Deadline to apply: 18 October 2016



ESTRO - VARIAN AWARD

A prize of € 5,000 will be given to a radiotherapy professional for research in the field of radiobiology, radiation physics, clinical radiotherapy or radiation technology.

CRITERIA FOR ELIGIBILITY

- Candidates should be ESTRO members, having completed the submitted work in the previous year.
- Submissions should be brought forward by the candidates or their department heads and may be work done as an individual piece of research or as a thesis complete in the field of biological, physical and clinical research.
- Candidates should be younger than 36. Exceptions will be made for female applicants who had to interrupt their research for pregnancy/maternity reasons; for them the maximum age is fixed at 40.

HOW TO APPLY

Candidates should submit:

- A curriculum vitae and a list of publications
- A copy of the abstract on the project which should have been submitted for ESTRO 36 (indicate abstract title and submitting author with your application)
- A summary (in English) of their work (max 2 pages).

Candidates should commit themselves to write an original paper in English on (part of) the scientific work carried out. This paper should be based on previously unpublished data and should be written according to the “Instructions to authors” of the Journal *Radiotherapy & Oncology* in which it will be published if accepted.

Deadline to apply: 18 October 2016



ESTRO-ELEKTA BRACHYTHERAPY AWARD

By submitting a brachytherapy abstract for ESTRO 36, you are automatically being considered for the “ESTRO-Elekta Brachytherapy Award”. Abstracts accepted for oral presentation for the brachytherapy track of ESTRO 36 will be considered for the award. Since the selection of the winner will be based only on the data provided in the abstract (and not on the presentation) it is advisable that you draft your abstract with extreme care, providing sufficient data for the evaluation by the jury.

The award will be given to the most innovative paper submitted for presentation in the brachytherapy track of ESTRO 36. The winning abstract will be selected by the ESTRO 36 Scientific Advisory Group for brachytherapy. The winner will be notified by email and announced in the ESTRO 36 Programme Book and Exhibition Guide (electronic format). The award amounts to € 2,000.

GEC-ESTRO BEST JUNIOR PRESENTATION

Sponsored by Elekta Brachytherapy

This award amounts to € 1,500 and is sponsored by Elekta Brachytherapy. The winning abstract will be selected by the ESTRO 36 Scientific Advisory Group for brachytherapy. The winner will be notified by email and announced in the ESTRO 36 programme book and exhibition guide (electronic format).

HOW TO APPLY

Applicants should be ESTRO members currently in training. If you meet this criterion, please send a copy of the abstract submitted for the brachytherapy track of ESTRO 36 and, a covering letter from the Head of department stating that the work has been done by the member in training, to eralda.azizaj@estro.org.

Deadline to apply: 18 October 2016

JUNIOR BRACHYTHERAPY TRAVEL GRANTS

Sponsored by Elekta Brachytherapy

ESTRO members currently in training who need support to attend the meeting may apply for the Junior Brachytherapy Travel Grants sponsored by Elekta Brachytherapy. Five grants of € 1,000 are available.

HOW TO APPLY

Candidates should submit:

- A motivation letter indicating your interest in brachytherapy and the reasons why you should be considered for this grant
- A covering letter from the department head stating that the work has been done by the member in training.
- Applications should be sent to eralda.azizaj@estro.org. Please indicate your full name, age and ESTRO membership type with your letter.

Deadline to apply: 18 October 2016

Applications for the above listed awards are to be addressed to:

ESTRO Office
Attn: Eralda Azizaj
Rue Martin V 40
1200 Brussels, Belgium

Tel: +32 2 775 93 40
Fax: +32 2 779 54 94
E-mail: eralda.azizaj@estro.org

GENERAL INFORMATION

UPDATED INFORMATION

Please consult the ESTRO website on a regular basis for updated information. Updates are also announced on the ESTRO Twitter and Facebook accounts.

CALL FOR ABSTRACTS

Abstracts must be submitted online through the ESTRO website which hosts an electronic abstract submission form. **Deadline for abstract submission is 24 October 2016.**

ONLINE REGISTRATION

Registration to the conference will be exclusively through our online registration form via the ESTRO website.

VENUE

Reed Messe Vienna GmbH Congress Center
Messeplatz 1
A-1021 Vienna, Austria

ACCOMMODATION

Mondial Congress & Events is the appointed official housing agent for ESTRO 36 and has blocked a variety of hotel rooms at attractive rates. Make sure you secure a room at your preferred hotel as soon as possible as availability is limited. Information on available hotels, rates as well as a convenient hotel map can be found online on the congress website.

CME ACCREDITATION

The conference organisers will apply for CME accreditation with the European Accreditation Council for Continuing Medical Education (EACCME).

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

CURRENCY

The currency in Austria is the euro (€).

OFFICIAL LANGUAGE

The official language of the congress is English. No simultaneous translation will be provided.

POSTERS

Electronic poster stations will allow you to view the virtual displays at your leisure and to correspond with presenters or forward a presentation to a colleague or your home office.

A limited number of posters will also be displayed in the poster area during the whole congress.

EXHIBITION

An exhibition featuring equipment and medical publishers will be held in the exhibition area. The opening of the exhibition will be on Friday 5 May 2017 at 19.30. The exhibition will remain open from Friday 5 May to Monday 8 May. Entrance is free for all registered participants. Companies and publishers who would like to participate in the exhibition may obtain more detailed information from the ESTRO Office.

Contact person

Valerie Cremades – Corporate Relations Manager
Tel.: +32 2 775 93 41
Fax.: +32 2 779 54 94
E-mail: vcremades@estro.org

INSURANCE

The organiser does not accept liability for individual medical, travel or personal insurance. Participants are strongly advised to take out their own personal insurance policies. In case an unforeseen event would force ESTRO to cancel the meeting, the Society will reimburse the participants the registration fee minus 15% for handling charges. ESTRO will not be responsible for the refund of travel and accommodation costs.

LUNCHEONS AND REFRESHMENTS

The registration fee for the conference includes coffee breaks to all participants and exhibitors wearing their conference badges. Lunch will be available for purchase in the exhibition area and is not included in the registration.

OPENING CEREMONY & WELCOME NETWORKING

All participants and company delegates are invited to the official opening ceremony which will be held in the main auditorium on Friday 5 May 2017 at 18:00. The opening ceremony will be followed by the welcome networking, which will take place in the exhibition area.

SATELLITE SYMPOSIA

Commercial satellite symposia will be held during lunch breaks. The programmes of the symposia will be published in the official programme book, on the ESTRO website and ESTRO 36 app. For additional information, please do not hesitate to contact:

Valerie Cremades – Corporate Relations Manager
Tel.: +32 2 775 93 41
Fax.: +32 2 779 54 94
E-mail: vcremades@estro.org

SOCIAL ACTIVITIES

Friday 5 May 2017

All registered participants and all company delegates are invited to the welcome networking which will take place in the exhibition area as of 19:30 on Friday 5 May.

Saturday 6 May 2017

All participants and company delegates are invited to the poster awards ceremony, which will be held in the poster area on Saturday 6 May at 18:30.

Sunday 7 May 2017

The 3rd Super Run will take place on Sunday 7 May at 19:00. The run is organised for the benefit of the ESTRO Cancer Foundation.

Monday 8 May 2017

All participants are invited to the after dinner evening which will take place in an exclusive venue in Vienna.

TRANSPORTATION TO VIENNA

One of the big advantages of the Messe Wien Exhibition & Congress Center is its inner city location. The venue is served by two underground stations, a stone's throw from the three main entrances.

The Congress Centre also has excellent links with the airport, the motorway and rail networks. Just 20 minutes by taxi from Vienna International Airport, it is sandwiched between the Prater park and the nearby Danube. The historic city centre is only a few minutes away by underground.

HOW TO REACH THE CONFERENCE CENTRE BY CAR

GPS: 1020 Vienna, Ausstellungsstraße or Trabrennsstraße

From the south: Südautobahn A2 - Südosttangente A23 in the direction of Praha/Brno – exit Handelskai/Messezentrum.

From the east (Wien-Schwechat Airport): Ostautobahn A4 – Südosttangente A23 in the direction of Praha/Brno - exit Handelskai/Messezentrum.

From the west: Westautobahn A1 until the motorway junction at Steinhäusl – Außenringautobahn A21 until the mo-

torway junction at Vösendorf – Südosttangente A23 in the direction of Praha/Brno - exit Handelskai/Messezentrum. From the north: Donauuferautobahn A22 until the exit for Reichsbrücke (direction Zentrum) – after the bridge turn left at the first traffic light into Vorgartenstraße and drive to the junction to Ausstellungsstraße.

BY AIR

With public transport systems from Vienna Airport (VIE) to Messe Wien Exhibition & Congress Center **CAT “CITY AIRPORT TRAIN”** to Wien Mitte/Landstraße – take the U4 line in direction Heiligenstadt – get out at Schottenring – take the U2 line in direction Aspernstraße.

SCHNELLBAHN S7 in direction Südbahnhof – get out at Praterstern – take the U2 line in direction Aspernstraße **BUS “VIENNA AIRPORT LINES”** to Morzinplatz – take the tramway 1 in direction Stefan-Fadinger-Platz - get out at Schottenring – take the U2 line in direction Aspernstraße.

BY RAIL

With public transport systems from the Vienna Railway Stations to Messe Wien Exhibition & Congress Center

SÜD/OSTBAHNHOF (under construction) – Replacement: Meidling/Philadelphiabrücke:

- **UNDERGROUND U6** in direction Floridsdorf to Längenfeldgasse – U4 line in direction Heiligenstadt to Schottenring – U2 line in direction Seestadt
- **SCHNELLBAHN** to Praterstern - U2 line in direction Seestadt

WESTBAHNHOF

- **UNDERGROUND U3** in direction Simmering to Volkstheater - U2 line in direction Seestadt

FRANZ-JOSEFS-BAHNHOF

TRAMWAY

- line 5 in direction Praterstern to Praterstern – U2 line in direction Seestadt
- line D in direction Südbahnhof to Schottentor - U2 line in direction Seestadt
- line 33 in direction Friedrich-Engels-Platz to Friedensbrücke – U4 line in direction Hütteldorf to Schottenring - U2 line in direction Seestadt

BAHNHOF PRATERSTERN (ehem. Bahnhof Wien Nord) **UNDERGROUND U2** in direction Seestadt

BY PUBLIC TRANSPORT

- **U2 UNDERGROUND LINE** „Karlsplatz – Seestadt“
The ideal exit to entrances A and Congress Center: station „Messe-Prater“
The ideal exit to entrance D: station „Krieau“
- **BUS line 11A** „Heiligenstadt - Seestadt“
exit to all entrances: station „Krieau“
- **BUS line 80B** „Kaiserebersdorf - Seestadt“
exit to all entrances: station „Krieau“

REGISTRATION

ONLINE REGISTRATION

Registering through the ESTRO website is simple and will only take a few minutes. The ESTRO website can be consulted at www.estro.org (click “Congresses and Meetings”, “ESTRO 36” and then “registration”). Please follow the instructions included on the electronic registration form before submitting your registration and do not send it again by fax or post. Receipt of registration will be acknowledged electronically.

PAYMENT INFORMATION

Payments can be made by credit card through our secured website. For all questions concerning registration and payments, please contact: events@estro.org

REGISTRATION FEE

Reduced fees apply when the payment is received before specific deadlines:

Early registration rate deadline: **18 January 2017**

Late registration rate deadline: **4 April 2017**

Desk registration rate: **as of 5 April 2017**

Please note that in order to benefit from the member price, you must renew your membership for 2017 before registering to the conference. The membership renewal should be done at least 3 days before the early or late deadlines. The membership internal processing and approval process might take up to maximum 3 working days.

The registration fee to the conference includes access to the scientific sessions and exhibition area, coffee breaks, the invitation to the opening ceremony, welcome reception and social evening. The fee does not include lunch. Lunch will be available for purchase in the exhibition area.

Registration to ESTRO 36 does not give access to the pre-congress courses and the contouring workshops. For these separate registrations are required.



Prices DO NOT INCLUDE VAT | 20% VAT will be added during the registration process

CONGRESS	EARLY	LATE	DESK
Deadlines	18 January 2017	4 April 2017	As of 5 April 2017
1 day In Training member	€ 200	€ 200	€ 200
1 day ESTRO member	€ 150	€ 300	€ 300
1 day non member	€ 415	€ 415	€ 415
Student ¹ /In Training member	€ 250	250	€ 250
ESTRO members from emerging countries ³	€ 300	300	-
Member	€ 355	540	€ 690
Non member	€ 600	780	€ 960

Pre-Congress courses

In Training member/student	€ 115	€ 165	€ 235
Member	€ 160	€ 200	€ 255
Non member	€ 205	€ 245	€ 300

Contouring workshop

In Training member/Student	€ 75
Member	€ 100
Non member	€ 150

Each additional contouring workshop

In Training member/Student	€ 25
Members	€ 40
Non-members	€ 50

¹To register as a student you should be an ESTRO member and send your valid student card to events@estro.org BEFORE completing the registration. Institute letters are not accepted.

²Members with speciality RTT may register at the In Training fee.

³Members from emerging countries may register at a preferential rate BEFORE 4 April 2017. After this date the desk fee will apply. Emerging country rate applies to individuals from low-income and lower-middle-income economies according to the World Bank listing available at: <http://data.worldbank.org/about/country-classifications/country-and-lending-groups>

CONFIRMATION OF REGISTRATION

Upon receipt of your registration form, a confirmation of your registration will be forwarded to you electronically.

CANCELLATION OF REGISTRATION

In case of cancellation, a full refund of the registration fee minus handling charges of 15% may be obtained up to 3 months before the meeting. Between 3 months and 1 month before the meeting, the refund will amount to 50% of the fee. No refund will be possible if the cancellation is postmarked after 5 April 2017.

NOT TO BE MISSED...

2017 ESTRO COMMUNITIES PAVILION

The other place for networking...



All delegates will be invited to the Communities Pavilion located in the exhibition area at ESTRO 36. Created to foster exchanges about science, projects, collaborations, and why not, job opportunities, the Communities Pavilion provides a networking forum for the wide range of stakeholders in radiation oncology.

Based on the success of the Cancer Centres Pavilion introduced at ESTRO 35 in Turin, the concept of this activity has been extended under the new name of Communities Pavilion to include this year national societies, international professional, scientific and patients associations, in addition to institutions, each represented within one booth.

Free access

No registration required

Dates: 5-8 May 2017

Exhibition opening hours

To book a booth on the Communities Pavilion, please contact atyszkiewicz@estro.org, ESTRO Public Affairs Co-ordinator.


SUPER RUN

Actioned by the ESTRO Cancer Foundation



Sunday 7 May 2017, 19.00 hrs

It has now become a not to be missed gathering at the ESTRO congress: the Super Run. Organised by the ESTRO Cancer Foundation, the Super Run raises awareness of radiotherapy. With 500 runners, including patients who are demonstrating that being physically active during treatment is possible, the Super Run is the opportunity to meet altogether in a congenial atmosphere and share the same effort in the fight against cancer.



ONE PICTURE BRINGS EVERYTHING INTO FOCUS

Velocity brings the whole picture into view for faster, more informed decisions.

Today's cancer care teams have access to a steady stream of patient data—but limited time to synthesize and share it. Velocity™ brings all imaging scans and treatment information together into a consolidated view that transforms disconnected data into actionable clinical knowledge. Created by radiation oncology veterans, Velocity is built on insight into clinical workflows and treatment planning. It's designed to make complex decision-making faster and collaboration easier:

Inside and outside the network. Today and tomorrow.

© 2016 Varian Medical Systems, Inc. All rights reserved. Varian and Varian Medical Systems are registered trademarks, and Velocity is a trademark of Varian Medical Systems, Inc.



Learn more at varian.com/velocity
www.varian.com info.europe@varian.com

VARIAN
medical systems

ESTRO MEMBERSHIP

Discover the opportunities that only the ESTRO membership can bring to you, your career, your practice, your profession, and ultimately, your patients.

ESTRO is devoted to advancing the goals of radiation oncology. This includes providing its members with outstanding science and education in order to support them in their career advancement.

Join ESTRO and gain access to exclusive member benefits such as:

- Online subscription to *Radiotherapy and Oncology*
- Reduced fees for attending ESTRO courses, conferences and joint events
- Online access to scientific material (events webcasts, delineation cases, etc.) through the e-library (DOVE)
- Eligibility for grants, awards, faculties and governance positions.

Add your voice to the 6,500 ESTRO members

ESTRO members are professionals of radiation oncology and beyond: radiation oncologists, clinical oncologists, medical physicists, radiobiologists, radiation therapists (RTTs), dosimetrists, radiotherapy nurses, medical oncologists, surgeons, industry representatives, organ specialists, other medical and non medical professions, coming from more than 100 countries spread all over the world.

ESTRO offers several categories of membership to fit your professional needs:

INDIVIDUAL MEMBERSHIP

FULL MEMBERSHIP

Multiple Year Fee: Full members may sign up or renew for two consecutive years and receive a final discount on the member registration fee

- **ACTIVE (€ 95 for 1 year or € 170 for 2 consecutive years):** You wish to access all the services ESTRO has on offer: subscription to *Radiotherapy & Oncology* (electronic and printed upon request), reduced fees for attending ESTRO and joint conferences and teaching courses, online access to e-contouring cases, publications and scientific information through our e-library (DOVE), eligibility for grants, awards, working groups, governance positions, voting rights and much more.
- **SUPPORTING AMBASSADOR (€ 250 for 1 year or € 450 for 2 consecutive years):** You wish to be strongly committed to the society by contributing to the ESTRO's Ambassador Solidarity Fund. You will have the same benefits as an Active member plus access to the available educational material produced by ESTRO school, immediate access to the ESTRO events webcasts, access to the VIP registration desk and VIP lounge at the ESTRO annual congress.

ASSOCIATE MEMBERSHIP

- **IN TRAINING (€ 75):** You can benefit from a large range of services and specific reduced fees for attending ESTRO conferences, teaching courses and joint events. To be eligible, you should be under the age of 40, have a relevant university diploma granted less than 10 years ago and currently be in training or enrolled in a full time PhD programme in a European institute.
- **AFFILIATE (€ 55):** You do not require full involvement in the Society but still wish to enjoy some of the more basic advantages on offer. You will have access to *Radiotherapy & Oncology* (electronic) and to one reduced fee per year at an ESTRO event or teaching course.
- **CORPORATE REPRESENTATIVE (€ 55):** This category is reserved for individual members working for a company and offers them access to the *Green Journal* (electronic) and to one reduced fee per year at an ESTRO event or teaching course.

More info on estro.org/members | Please register online via www.estro.org



INSTITUTIONAL MEMBERSHIP

ESTRO offers European institutes the possibility to pay collectively for the membership of their employees (minimum of 5), who will enjoy all the usual advantages of the individual membership. This is the most cost-effective option for institutes who will also benefit from a host of advantages such as a dedicated promotional webpage on the ESTRO website and in the newsletter, a monthly ESTRO public affairs newsletter exclusively tailored to their needs, and the privilege to apply for a free exhibiting booth at the annual event (Communities Pavilion).

More info on estro.org/members | To register, please contact institutional-membership@estro.org

DUAL MEMBERSHIP

This category can be granted to individual members who benefit from a joint membership agreement, signed on a case by case basis between ESTRO and a non-European national society or a European young national society. We invite you to check with your national society whether they have an agreement with ESTRO.

CORPORATE MEMBERSHIP

ESTRO has a membership programme dedicated for companies who can opt for either regular or gold membership. Gold membership gives the right to seat in the ESTRO corporate council that serves to facilitate the collaboration and coordination between the research and development activities of the companies and the academic and scientific developments within ESTRO.

More info on estro.org/members | To register, please contact corporate@estro.org

ESTRO membership runs from the 1st of January to the 31st of December. Radiation therapists (RTTs), dosimetrists, radiotherapy nurses belong to all membership categories without distinction of disciplines. When registering for ESTRO events, whatever the membership category they belong to, they will benefit from the In Training rate.

We strongly advise you to renew your membership at least 3 days before the early and late course/event deadlines. The members' rates will only be applied once the payment has been finalised and processed. For any question, please contact membership@estro.org.

LOOKING FOR SCIENTIFIC MATERIAL?

It's probably on DOVE...



DOVE

THE ESTRO PLATFORM FOR SCIENTIFIC AND EDUCATIONAL DATA

DOVE is the e-library developed by ESTRO giving you access to educational and scientific material, produced and disseminated by the Society: *Radiotherapy & Oncology* articles, conference abstracts, webcasts, posters, access to FALCON (the ESTRO delineation platform), guidelines, our newsletter, EU projects...

HOW DOES IT WORK?

DOVE works as a search engine encompassing all kinds of data in radiation oncology. Just type in your key words and then refine your search by ticking the boxes if you are looking for a particular type of support (abstract, webcast...). Or simply type a key word to see all the information available linked to the topic.

HOW TO ACCESS DOVE?

Simply go to www.estro.org: The DOVE search field appears on the welcome page. The level of free access to the content you searched will depend on your membership type and participation to ESTRO events.

WWW.ESTRO.ORG



ESTRO 36 APP

NO PRINTED PROGRAMME BOOK ON SITE

We encourage you to download the app a few weeks before the congress.

Download the free ESTRO 36 mobile and tablet app and take advantage of the full event schedule, as well as the personalised agenda, networking function and exhibition listings. Wifi will be available in the main auditoriums.



DOWNLOADABLE IN APRIL 2017



SESSIONS

You can check out the sessions you wish to attend, view their summary and add them to your personal agenda.



SPEAKERS

You can view biographies, select congress speakers, send them messages and add them to your own personal agenda.



MY EVENT

This is your personal agenda, displaying your selected sessions, speakers, exhibitors and much more.



EXHIBITION

Thanks to the interactive floor plan, you can easily access the information on the booths and exhibitors you wish to visit and save them to your personal agenda.



NETWORKING

You can create your own profile, which gives you the opportunity to interact with other attendees at the event via the messaging service. You can send messages privately and arrange meetings that will be scheduled in your personal agenda.



SOCIAL MEDIA

Stay up-to-date with the latest congress news by using Twitter (#ESTRO36) and Facebook.



ABSTRACT BOOK

The abstract book will be directly downloadable from the app.

